- Home
- CAG vs EXEL Comparison
CAG vs EXEL Comparison
Compare CAG & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAG
- EXEL
- Stock Information
- Founded
- CAG 1919
- EXEL 1994
- Country
- CAG United States
- EXEL United States
- Employees
- CAG N/A
- EXEL N/A
- Industry
- CAG Packaged Foods
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CAG Consumer Staples
- EXEL Health Care
- Exchange
- CAG Nasdaq
- EXEL Nasdaq
- Market Cap
- CAG 9.3B
- EXEL 10.4B
- IPO Year
- CAG N/A
- EXEL 2000
- Fundamental
- Price
- CAG $17.16
- EXEL $39.50
- Analyst Decision
- CAG Hold
- EXEL Buy
- Analyst Count
- CAG 11
- EXEL 22
- Target Price
- CAG $21.64
- EXEL $44.10
- AVG Volume (30 Days)
- CAG 11.3M
- EXEL 2.9M
- Earning Date
- CAG 12-18-2025
- EXEL 11-04-2025
- Dividend Yield
- CAG 8.05%
- EXEL N/A
- EPS Growth
- CAG 73.36
- EXEL 81.76
- EPS
- CAG 1.77
- EXEL 2.08
- Revenue
- CAG $11,450,500,000.00
- EXEL $2,230,005,000.00
- Revenue This Year
- CAG N/A
- EXEL $9.14
- Revenue Next Year
- CAG N/A
- EXEL $12.59
- P/E Ratio
- CAG $9.82
- EXEL $18.99
- Revenue Growth
- CAG N/A
- EXEL 10.73
- 52 Week Low
- CAG $17.35
- EXEL $28.30
- 52 Week High
- CAG $29.86
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- CAG 31.89
- EXEL 53.00
- Support Level
- CAG $18.26
- EXEL $33.76
- Resistance Level
- CAG $18.99
- EXEL $40.63
- Average True Range (ATR)
- CAG 0.39
- EXEL 1.26
- MACD
- CAG -0.12
- EXEL 0.21
- Stochastic Oscillator
- CAG 9.43
- EXEL 83.62
About CAG ConAgra Brands Inc.
Conagra Brands is a packaged food company that operates predominantly in the United States (91% of fiscal 2025 revenue). Most of its revenue comes from frozen food, including brands like Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Conagra also sells snacks, shelf-stable staples, and refrigerated food through brands like Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. The company primarily sells through the US retail channel, with just 9% of fiscal 2025 revenue coming from international markets and 9% from foodservice.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.